In a previous report, Shalapour et al.44 showed that OxP treatment increased CXCL13 levels in prostate cancer and recruited immunosuppressive plasma cells to the tumor, which would impede the T-cell-dependent immunogenic chemotherapy. The gene discussed is CXCL13; the disease is prostate carcinoma.